-+ 0.00%
-+ 0.00%
-+ 0.00%
Alnylam-Discovered Livsayis Wins FDA Approval for Generalized Myasthenia Gravis
Share
Listen to the news
Alnylam-Discovered Livsayis Wins FDA Approval for Generalized Myasthenia Gravis
  • The FDA approved Alnylam-discovered Livsayis (cemdisiran) for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
  • The approval triggers a $25 million payment from Regeneron, with tiered, double-digit royalties of up to 15% on global net sales.
  • Regeneron will commercialize the treatment, having assumed sole responsibility for development, manufacturing and commercialization in 2024.
  • Livsayis is the platform’s seventh FDA-approved therapy in less than nine years and the first RNAi treatment cleared for generalized myasthenia gravis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611190700BIZWIRE_USPR_____20261119_BW295782) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending